effect of vitamins E and C on lipid profile in elderly

Not Applicable

Conditions: Condition 1: Pure hypercholesterolaemia. Condition 2: Mixed hyperlipidaemia. Condition 3: Other hyperlipidaemia. Condition 4: Lipoprotein deficiency. Condition 5: Hyperlipidaemia, unspecified.
Familial hypercholesterolaemiaFredrickson hyperlipoproteinaemia, type IIaHyperbetalipoproteinaemiaHyperlipidaemia, group ALow-density-lipoprotein-type [LDL] hyperlipoproteinaemia
Broad- or floating-betalipoproteinaemiaFredrickson hyperlipoproteinaemia, type IIb or IIIHyperbetalipoproteinaemia with prebetalipoproteinaemiaHypercholesterolaemia with endogenous hyperglyceridaemiaHyperlipidaemia, group CTubero-eruptive xanthomaXanthoma
Familial combined hyperlipidaemia
AbetalipoproteinaemiaHigh-density lipoprotein deficiencyHypoalphalipoproteinaemiaHypobetalipoproteinaemia (familial)Lecithin cholesterol acyltransferase deficiencyTangier disease

Registration Number: IRCT2014052517831N1

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 210

Inclusion Criteria

Age between 60 to 75 years; literacy rate higher than fifth grade; Exclusion criteria:The lack of a liver disorder, renal failure and mal absorption, any kind of cancer, or any illness that may interfere with the absorption of antioxidants; Smoking, tobacco and drug abuse; taking Vitamin C and E supplementation before entering the study; taking medications that could seriously disrupt lipid metabolism, such as fibrates, nicotinic acid, glucocorticoids; those who at baseline diagnosed hyperlipidemic of course with The experiment was done, and did not receive a medication to control it and required medication; severe disability

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total cholestrol. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry.;LDL. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry.;HDL. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry.;TG. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry.

Secondary Outcome Measures